Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →FDA granted fast-track designation to evofosfamide for advanced pancreatic cancer, validating the hypoxia-activated prodrug approach pursued under the Merck…
Merck KGaA, Darmstadt, Germany decided not to pursue evofosfamide further in soft tissue sarcoma and pancreatic cancer following Phase 3 trial failures.
Threshold partnered with Merck KGaA in 2012 in a global license and co-development agreement; Merck abandoned attempts to commercialize evofosfamide in…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Merck Serono (Merck KGaA) and Threshold global agreement to co-develop/commercialize TH-302. $25M upfront plus up to $35M near-term development milestones; $525M total milestone potential ($280M dev/reg + $245M sales). Merck pays 70% of worldwide development costs.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Merck KGaA / Threshold Pharmaceuticals, Inc. (this deal) | 2012 | $550M | — |
| Merck KGaA / Millipore Corporation | 2010 | $7.2B | 88 |
| Merck KGaA / Sigma-Aldrich Corporation | 2014 | $17.0B | 80 |
| Merck KGaA / Versum Materials | 2019 | $5.8B | 80 |
| Merck KGaA / Serono SA | 2006 | $13.2B | 74 |
| Merck KGaA / SpringWorks Therapeutics | 2025 | $3.4B | 72 |
| Merck KGaA / Debiopharm | 2021 | $1.1B | — |
← Browse all deals · How we score deals
More: 2012 deals · Merck KGaA deals · Oncology deals